Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound.

Next Previous
Trial Profile

Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atorvastatin (Primary) ; Ezetimibe (Primary)
  • Indications Atherosclerosis; Coronary artery disease; Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms PRECISE-IVUS

Most Recent Events

  • 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association
  • 17 Apr 2013 Planned End Date changed from 1 Jan 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
  • 02 Feb 2013 Primay endpoint amended as reported by University Hospital Medical Information Network - Japan record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top